Gilead Sciences (GILD) Misses Q4 EPS by 83c; Offers 2022 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Gilead Sciences (GILD) Misses Q4 EPS by 83c; Offers 2022 Guidance

Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

February 1, 2022 4:02 PM EST

Biktarvy Sales Increased Year-Over-Year by 19% for Full Year 2021 & 22% for Fourth Quarter 2021

EPS Results Reflect $1.25 Billion Charge for a Legal Settlement & $625 Million Arcus Opt-In Charge

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2021.

Gilead is at an important point in its transformation journey, having built considerable momentum in the expansion of our commercial and clinical portfolios in both virology and oncology in 2021, said Daniel ODay, Gileads Chairman and... More